lung surfactant


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to lung surfactant: Pulmonary surfactant, lung surfactant drugs

lung surfactant

a detergent-like agent that reduces the surface tension of the liquid film covering the inner lining of the pulmonary alveoli. As an alveolus becomes smaller during expiration, the surfactant becomes more concentrated, further reducing the surface tension and preventing alveolar collapse.

surfactant

(sur-fak'tant) [ surf(ace)-act(ive) a(ge)nt]
A surface-active agent that lowers surface tension (e.g., oils and various forms of detergents). Artificial surfactants may be given endotracheally to relieve respiratory distress.

lung surfactant

Pulmonary surfactant.

modified natural surfactant

A replacement phospholipid from a natural source with some components removed.

pulmonary surfactant

A lipoprotein secreted by type II alveolar cells that decreases the surface tension of the fluid lining the alveoli, permitting expansion. Synthetic lung surfactant is available for treating patients with respiratory distress syndrome. In obstetrics, fetal production of surfactant can be stimulated by administration of a glucocorticoid 24 to 48 hr before an inevitable preterm birth.
Synonym: lung surfactant See: betamethasone; lecithin-sphingomyelin ratio
References in periodicals archive ?
A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
There is need to evaluate the role of other mediators in regulating the production of inflammatory mediators in the lung, perhaps the role of lung surfactant.
Influence of Pulmonary Surfactant Protein Mimics on Model Lung Surfactant
Discovery Laboratories (NASDAQ:DSCO) develops humanized lung surfactant as a surfactant replacement therapy (SRT) for respiratory diseases.
a public biopharmaceutical company that is developing a new humanized lung surfactant technology and currently awaiting marketing approval from the FDA.
a public biopharmaceutical company that developed a new humanized lung surfactant technology that is awaiting marketing approval from the FDA.
Discovery Labs (NASDAQ:DSCO) is developing a proprietary humanized lung surfactant for respiratory diseases and surfactant replacement therapies.
Pumactant was originally developed by Britannia in 1987 as a lung surfactant for Infant Respiratory Distress Syndrome and licensed in the UK as ALEC(R).
It was originally developed by Britannia as a lung surfactant for Infant Respiratory Distress Syndrome and licensed in the UK as ALEC(R).
Surfaxin(R) is a novel, peptide-containing lung surfactant invented at The Scripps Research Institute.
Surfaxin(TM) is a novel, peptide-containing lung surfactant invented at The Scripps Research Institute.